NCT04446117Phase 3Active not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Study sponsor: Exelixis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-04-19Actual

Enrollment · participants575Actual

Source updated2025-12-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-12-11 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Duration of Progression Free Survival per Response Evaluable Criteria in Solid Tumors version 1.1 (RECIST 1.1); measure: Duration of Overall Survival (OS)

+ Updated value

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Metastatic Prostate Cancer; Prostate Adenocarcinoma

Treatments or interventions studied

CabozantinibDrugAlso known as XL184, Cabometyx®
AtezolizumabDrugAlso known as Tecentriq®
Abiraterone AcetateDrugAlso known as Abiraterone, Zytiga
EnzalutamideDrugAlso known as Xtandi
PrednisoneDrug

Primary outcomes · main study measures

Read the study measures

measure: Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC); description: Duration of PFS was defined as the time from randomization to the earlier of either the date of radiographic progression (defined as progressive disease \[PD\] per RECIST 1.1) per BIRC or the date of death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions, with an absolute increase of ≥ 5 mm, unequivocal progression of non-target lesions and/or the appearance of new lesions.; timeFrame: Up to a maximum of approximately 30 months (Median duration of follow-up was 14.31 months); measure: Duration of Overall Survival (OS); description: Duration of OS was defined as the time from randomization to death due to any cause. For participants, who were not known to have died at the time of data cutoff and were permanently lost to follow-up, duration of OS was censored at the earlier of the following dates: date the participant was last known to be alive or date of full withdrawal of consent (including survival follow-up), or date of data cutoff. OS was calculated as earlier of date of death or censoring - date of randomization + 1)/30.4375; timeFrame: Up to a maximum of approximately 45 months (Median duration of follow-up was 24.05 months)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history